NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE184055 Query DataSets for GSE184055
Status Public on Sep 23, 2022
Title Hepatic thyroid hormone signalling modulates glucose homeostasis through the regulation of GLP-1 production via bile acid-mediated FXR antagonism
Organism Mus musculus
Experiment type Expression profiling by array
Summary A greater understanding of the glucose homeostasis mediated by glucagon-like peptide-1 (GLP-1) will facilitate the development of novel glucose-lowering treatments. Here we show that improved glucose metabolism in hypothyroid mice after treatment of T3, the active form of thyroid hormone (TH), is accompanied with increased GLP-1 production and insulin secretion. Treatment of a GLP-1 receptor antagonist is able to attenuate the observed T3 effect on insulin and glucose levels, suggesting that GLP-1 is critically involved in the regulation of glucose homeostasis by T3. By using a mouse model lacking hepatic TH receptor β (TRβ) and a liver-specific TRβ-selective agonist, we demonstrate that TRβ-mediated hepatic TH signalling is not only required for the regulation of GLP-1 production by T3 but also the insulinotropic and glucose-lowering effects of T3. Accordingly, administration of the liver-targeted TRβ-selective agonist is capable of increasing GLP-1 and insulin levels and alleviating hyperglycemia in diet-induced obesity. Mechanistically, through suppressing CYP8B1 expression, T3 shapes the bile acid (BA) composition and increases the levels of Farnesoid X receptor (FXR)-antagonistic BAs, thereby potentiating the GLP-1 production and insulin secretion by repressing intestinal FXR signalling. Consistently, correlations between the T3 levels and either GLP-1 or FXR-antagonistic BA levels can be observed in euthyroid human subjects. Thus, our study reveals a previously undescribed role of hepatic TH signalling in glucose homeostasis through the regulation of GLP-1 production via BA-mediated FXR antagonism, which will underpin the development of novel therapeutics.
 
Overall design There are two groups, fasting and feeding, one sample per group, and each sample is the pool of livers of three mice treated the same.
 
Contributor(s) Liu W, Yan Y, Niu Z, Sun C, Li P, Shen S, Liu S, Li Y, Fang Z, Zhao L, Jiang C, Jiang J, Ying H
Citation(s) 36302774
BioProject PRJNA762511
Submission date Sep 13, 2021
Last update date Nov 02, 2022
Contact name ying yan
E-mail(s) yanying2017@sibs.ac.cn
Organization name Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences
Street address 320 Yueyang Road, Shanghai
City Shanghai
ZIP/Postal code 200031
Country China
 
Platforms (1)
GPL10333 Agilent-026655 Whole Mouse Genome Microarray 4x44K v2 (Feature Number version)
Samples (2)
GSM5576915 fasting_rep1
GSM5576916 feeding_rep1

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE184055_RAW.tar 10.8 Mb (http)(custom) TAR (of TXT)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap